Conversely, tumor-intrinsic immune checkpoints' ligand like programmed death ligand-1 (PD-L1) can inhibit the activation of CTLs via binding to its receptor PD-1, resulting in the tumor immune evasion [8, 13]. Here, PDCD1 is linked to neoplasm.